The NSW-RPRN will actively engage with the broader research community, with a focus on those involved in RNA or medical research related to key application areas for RNA therapeutics such as vaccines, gene therapies and cancer. This includes collaborations with other NSW Office for Health and Medical Research supported activities and experts such as:
- Vaccine, Infection and Immunology (VIIM) Collaborative Research Group
- Cell & Molecular Therapies at Royal Prince Alfred Hospital
- Westmead Research Hub Cell and the clinical cell therapies service at the Westmead Institute for Medical Research (WIMR)
The NSW-RPRN will also work collaboratively with the whole NSW RNA community of practice through the NSW RNA Bioscience Alliance.
Locally and federally, we will seek to work with the TGA as it develops its capabilities to work with the emerging RNA ecosystem in Australia.
At the Federal level, several of the organisations involved in the NSW-RPRN are part of or receive some support from National Collaborative Research Infrastructure Strategy (NCRIS). Facilities such as Bioplatforms Australia (BPA) and Therapeutic Innovation Australia (TIA) are organisations that the NSW-RPRN intends to work closely with. The Australian Vaccine Response Alliance (AVRA) is another organisation that the NSW-RPRN sees as a priority collaborative partner. The national RNA R&D supporting network(s) that are likely to emerge from the Federal government’s recent “Approach to Market” call for population-scale mRNA vaccine manufacturing will be another avenue for NSW-RPRN to reach out to and work with as the national RNA ecosystem evolves.
The NSW-RPRN acknowledges the funding provided by NSW Health and the NSW Office of Health and Medical Research.
